# ZYDUSLIFE (ZYDUSLIFE) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/zyduslife

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,157.7
- Change: +1.99%
- As of: 2026-09-18
- 1D return: +2.19%
- 5D return: +3.78%
- 1M return: +4.72%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, ZYDUSLIFE is trading at ₹1160.0, showing a mixed technical picture across different timeframes. The daily and weekly timeframes indicate a bullish trend, with prices trading above key moving averages (EMA 20, EMA 50, SMA 20, SMA 50, SMA 200) and the Supertrend indicator. However, the monthly timeframe presents a conflicting bearish signal, with the price below the monthly Supertrend. Recent market activity includes two positive attention events in the last 30 days, with a moderate upward price movement accompanied by higher volume on September 18, 2026.

The stock is currently positioned within its recent trading range, with the price sitting above the 20-day and 50-day range positions but below the 252-day range position. Nearest support is identified at ₹1149.97, followed by ₹1125.03. Resistance is observed at ₹1164.83 and ₹1171.65. The stock exhibits an annualized volatility of 24% and a current drawdown of -4%, with a maximum drawdown of -19% observed historically. The presence of a "Morning Star" pattern on the weekly chart and a "Doji" on the monthly chart suggest potential indecision or reversal signals.

Key watch conditions include monitoring the price action around the ₹1164.83 resistance level. A sustained move above this level, especially with increased volume, could strengthen the bullish short-to-medium term outlook. Conversely, a break below the ₹1149.97 support level, particularly if accompanied by rising volume, might indicate further downside pressure, aligning with the bearish monthly trend signal.

- On September 18, 2026, ZYDUSLIFE closed at ₹1160.0.
- Daily and weekly timeframes show bullish trends, with prices above key moving averages and Supertrend.
- The monthly timeframe indicates a bearish trend, with the price below the monthly Supertrend.
- Nearest support levels are ₹1149.97 and ₹1125.03; nearest resistance levels are ₹1164.83 and ₹1171.65.
- Watch for price movement above ₹1164.83 or below ₹1149.97 for potential trend confirmation.

- Doji
- Morning Star
- Bearish Engulfing Reversal
- Bullish Engulfing Reversal
- Outside Bar
- Inside Bar

### What Changed

As of September 18, 2026, Zydus Lifesciences (ZYDUSLIFE) on the NSE has seen its stock price increase to ₹1160.0 from a previous price of ₹1135.1. This represents a recent upward movement in the stock's valuation. The company's profile and listing on the NSE remain consistent with prior context. No new filings or news developments were reported as of the observation date.

- On 2026-09-18, ZYDUSLIFE's stock price was ₹1160.0.
- The previous stock price for ZYDUSLIFE was ₹1135.1.
- The company is listed on the NSE.
- No new filings or news were reported as of 2026-09-18.

### Official Filings

Zydus Lifesciences Limited announced on August 31, 2026, positive topline results from its completed EVIDENCES-X Phase II(b) clinical trial for Saroglitazar Mg in MASH. This development is significant as it pertains to the potential efficacy of a new drug candidate. The company also disclosed on August 26, 2026, its intention to acquire companies that are yet to be incorporated, which could indicate future expansion or strategic initiatives. Additionally, on September 11, 2026, the company informed the exchange about an upcoming schedule of meetings with analysts and institutional investors, and also about its credit rating, which are standard updates for listed entities.

- On August 31, 2026, Zydus Lifesciences announced positive topline results from the EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg in MASH.
- On August 26, 2026, the company disclosed plans for the acquisition of to-be-incorporated companies.
- On September 11, 2026, Zydus Lifesciences provided updates regarding its credit rating.
- On September 11, 2026, the company informed the exchange about a schedule of meetings with analysts and institutional investors.

- Zydus Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Zydus Lifesciences Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating
- Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Zydus Lifesciences Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- Zydus Lifesciences Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH". |SUBJECT: Press Release
- Zydus Lifesciences Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- ZYDUS LIFESCIENCES LIMITED has informed the Exchange regarding Acquisition of to be incorporated companies |SUBJECT: Acquisition of 'to be incorporated companies'-XBRL
- Zydus Lifesciences Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- Zydus Lifesciences Limited has informed the Exchange regarding 'Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015'. |SUBJECT: Updates

### Fundamentals

Zydus Lifesciences (NSE) reported its financial results for the periods ending Q3 FY2025-26, Q4 FY2025-26, and Q1 FY2026-27. Revenue from operations showed an upward trend, increasing from ₹6,864.50 crore in Q3 FY2025-26 to ₹8,017 crore in Q1 FY2026-27. However, expenses also rose significantly, particularly in Q1 FY2026-27, reaching ₹6,798.30 crore compared to ₹5,537.60 crore in Q3 FY2025-26. This rise in expenses impacted profitability. Profit Before Exceptional Items And Tax saw fluctuations, peaking at ₹2,057.20 crore in Q4 FY2025-26 before declining to ₹1,324.80 crore in Q1 FY2026-27. Similarly, Profit Loss For Period decreased from ₹1,341 crore in Q4 FY2025-26 to ₹990.20 crore in Q1 FY2026-27. The profit from continuing operations followed a similar pattern, decreasing to ₹952.40 crore in Q1 FY2026-27 from ₹1,341.30 crore in Q4 FY2025-26. Investors may want to monitor the company's expense management and its impact on profit margins in upcoming quarters.

- Revenue from operations increased sequentially from ₹6,864.50 crore in Q3 FY2025-26 to ₹8,017 crore in Q1 FY2026-27.
- Expenses rose from ₹5,537.60 crore in Q3 FY2025-26 to ₹6,798.30 crore in Q1 FY2026-27.
- Profit Loss For Period declined to ₹990.20 crore in Q1 FY2026-27 from ₹1,341 crore in Q4 FY2025-26.
- Profit Loss For Period From Continuing Operations decreased to ₹952.40 crore in Q1 FY2026-27 from ₹1,341.30 crore in Q4 FY2025-26.

### Bull Case

The company's stock is exhibiting several constructive technical signals across different timeframes as of September 18, 2026. On a daily basis, the Supertrend indicator is bullish, and the 20-day Exponential Moving Average (EMA) shows a positive slope, suggesting upward momentum. This is further supported by a bullish Supertrend direction on the weekly timeframe, with both the 20-day and 50-day Simple Moving Averages (SMA) trending upwards. The stock has also demonstrated positive returns over various periods, including a 29% return in the last six months and a 27% year-to-date return, indicating recent market appreciation.

- Daily Supertrend indicator is 'bullish' as of September 18, 2026.
- Weekly trend shows a 'bullish' Supertrend direction.
- The stock has achieved a 29% return in the last six months.
- Year-to-date return stands at 27% as of September 18, 2026.

- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Dr Reddy’s launches Opdivo biosimilar Nivorz in India, enters immuno-oncology segment

### Bear Case

The company's monthly technical trend indicates a bearish signal, with the Supertrend indicator at ₹1167.31 suggesting a potential downward movement. This is further supported by a monthly ADX of 31.78, which can signify strong trending conditions, though the direction is indicated as bearish. While the daily trend shows a bullish Supertrend at ₹1091.06, the monthly perspective warrants caution. The stock is trading near its nearest resistance level of ₹1164.83, with a distance of 0.42%. Additionally, the company has experienced a maximum drawdown of -19%, indicating past periods of significant decline.

- Monthly technical trend shows a bearish Supertrend signal at ₹1167.31 as of 2026-09-18.
- The stock is trading close to its nearest resistance level of ₹1164.83, at a distance of 0.42%.
- The company has recorded a maximum drawdown of -19% historically.
- The monthly ADX value of 31.78 suggests strong trending conditions, which are currently indicated as bearish.

- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Dr Reddy’s launches Opdivo biosimilar Nivorz in India, enters immuno-oncology segment

### FAQs

**What are Zydus Lifesciences' recent technical trends and price levels?**

As of September 18, 2026, Zydus Lifesciences' daily technical trend is indicated as bullish, with the closing price at ₹1160.0, above the 20-day Exponential Moving Average (EMA) of ₹1134.82 and the 50-day EMA of ₹1125.56. The stock's SuperTrend indicator is also bullish at ₹1091.06. However, the monthly trend shows a bearish SuperTrend at ₹1167.31. Nearest resistance levels are observed at ₹1164.83 (0.42% away) and ₹1171.65 (1.0% away), while support is noted at ₹1149.97 (-0.86% away) and ₹1125.03 (-3.01% away).

**What has been Zydus Lifesciences' recent stock performance over different periods?**

Zydus Lifesciences has shown varied returns across different timeframes as of September 18, 2026. The stock has returned 2% in the last day, 4% in the last month, and 27% year-to-date. Over a longer horizon, it has returned 29% in the last six months and 11% in the last year. Returns over 3 months, 5 days, 10 days, and since the start of trading are 8%, 4%, 1%, and 19% respectively.

**What recent announcements has Zydus Lifesciences made?**

Zydus Lifesciences has informed the exchange about several updates. These include the schedule for an Analysts/Institutional Investor Meet/Con. Call on September 11, 2026, and information regarding its Credit Rating on the same date. Additionally, the company has published newspaper notifications and provided general updates on September 5, 2026, and September 1, 2026.

- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Dr Reddy’s launches Opdivo biosimilar Nivorz in India, enters immuno-oncology segment
- Zydus Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Zydus Lifesciences Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating
- Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Zydus Lifesciences Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- Zydus Lifesciences Limited has informed the Exchange about General Updates |SUBJECT: General Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,125.03
- Risk regime: Price Risk Currently Contained

### Support levels
- 968.3187499999999
- 942.25
- 939.4490478515625

### Resistance levels
- 1171.65
- 1201.95
- 1164.8333333333335

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +2.19% |
| return_10 | +1.49% |
| return_1m | +3.98% |
| return_1y | +10.70% |
| return_20 | +4.72% |
| return_3m | +7.97% |
| return_5 | +3.78% |
| return_6m | +28.95% |
| return_since_start | +19.12% |
| return_ytd | +26.77% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -18.64% |
| annualized_volatility | +24.33% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Grows 22% but Profit Declines 35% as Expenses Rise Faster

Zydus Lifesciences Limited reported a 22% year-on-year increase in revenue from operations to ₹8,017 crore for the quarter ended June 30, 2026. However, total expenses rose 41% to ₹6,798 crore, compressing margins and causing net profit to fall 35% to ₹990 crore. Finance costs nearly doubled from the year-ago period, adding to the pressure on the bottom line.

## Revenue Growth and Expense Dynamics

Revenue expanded 22% compared with the same quarter last year (₹6,574 crore) and grew 5.7% from the preceding March 2026 quarter. The upward trajectory in revenue has been sustained across the past four quarters.

Total expenses climbed 41% year-on-year—from ₹4,808 crore to ₹6,798 crore—and rose 20% sequentially. This lifted the expense-to-revenue ratio to 85%, up from 73% a year earlier, indicating a significant rise in the cost required to generate each rupee of sales.

## Profitability Compression

Profit before exceptional items and tax fell 31% year-on-year to ₹1,324.8 crore. After accounting for exceptional items, profit before tax declined 32% to ₹1,306.6 crore. On a sequential basis, profit before tax dropped 21% from the March 2026 quarter even though revenue was 5.7% higher.

Tax expenses added to the margin squeeze. The effective tax rate—calculated as tax expense divided by profit before tax—rose from 22.6% in the year-ago quarter to 27.1%. Consequently, net profit from continuing operations fell 36% to ₹952.4 crore, and basic earnings per share from continuing operations decreased to ₹9.35 from ₹14.58. Overall net profit for the period stood at ₹990 crore, a decline of 35%.

## Finance Costs and Exceptional Items

Finance costs surged 84% year-on-year to ₹156 crore and increased 27% from the immediately preceding quarter. The sharp rise in finance costs weighed further on profitability.

Exceptional items before tax in the quarter were a net charge of ₹18.2 crore, sharply lower than the ₹397.5 crore charge recorded in the March 2026 quarter. With the exceptional charge limited to a minimal amount, the decline in profit aligns directly with the sharp increase in total operating expenses.

## Management Commentary

Zydus Lifesciences reported Q1 FY27 revenue from operations of Rs 80,170 mn, up 22% YoY, driven by strong growth in India formulations (+20% YoY), Consumer Wellness (+67% YoY), and International Markets (+34% YoY). EBITDA margin was 24.1%, down 770 bps due to acquisition-related costs and higher R&D spend (8% of revenues). Net profit declined 36% YoY to Rs 9,398 mn. Management highlighted that the branded portfolio now exceeds 55% of revenues and that the US branded sales share reached 11%, set to expand with the upcoming Saroglitazar launch. Key strategic moves include the completed acquisition of Assertio Holdings to strengthen US specialty, the launch of first biosimilar NUFYMCO (Ranibizumab) in the US, and a joint venture in Sri Lanka for manufacturing. On the innovation front, the USFDA granted priority review for Saroglitazar NDA in Primary Biliary Cholangitis, and the company advanced several pipeline assets including Phase III trials for Desidustat in sickle cell disease and a second biosimilar ADC. Additionally, Sentynl (Zydus subsidiary) entered an option and license agreement for alvelestat, a potential first-in-class oral treatment for AATD-LD, with Sentynl obtaining U.S. commercial rights on option exercise.

## Key Takeaway

Zydus Lifesciences posted solid revenue growth this quarter, but a 41% surge in total expenses—more than double the rate of revenue growth—drove a 35% drop in net profit. Finance costs nearly doubled, and a higher effective tax rate further eroded earnings. The quarter’s results highlight how rapidly rising costs offset top-line gains, leaving margins under noticeable pressure.

### Ratios

## Official filings

- 2026-09-11 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_11092026114031_Investorconference11092026.pdf)
- 2026-09-11 — Credit Rating Update: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_11092026143115_SEIntimationcreditrating11092026.pdf)
- 2026-09-09 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_09092026135401_Newspaperadvertisement09092026.pdf)
- 2026-09-05 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_05092026171746_SEIntimationSettlementAgreementSep2026.pdf)
- 2026-09-01 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_01092026105757_Transcript.pdf)
- 2026-08-31 — Press Release: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_31082026104241_PressRelease31082026.pdf)
- 2026-08-26 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_26082026110958_IncorporationWOS.pdf)
- 2026-08-26 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_1852_WebXMLFile_20260826_135450312.xml)
- 2026-08-25 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_25082026165937_SEIntimationESGRatingCRISIL24082026.pdf)
- 2026-08-24 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_24082026193211_PITDisclosures24082026.pdf)
- 2026-08-24 — Official Filing: ZYDUS LIFESCIENCES LIMITED — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_1852_WebXMLFile_20260824_194539995.xml)
- 2026-08-23 — Earnings Presentation: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_23082026123836_InvestorPresentation24082026CLS.pdf)
- 2026-08-21 — Press Release: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_21082026135055_PressRelease21082026.pdf)
- 2026-08-18 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_18082026145349_IntimationofPostResultsEarningsCallTranscript11082026.pdf)
- 2026-08-17 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_17082026160326_Investorconference17082026.pdf)
- 2026-08-12 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_12082026170250_Investorconference12082026.pdf)
- 2026-08-12 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_12082026134749_NewspaperPublication.pdf)
- 2026-08-11 — Press Release: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_11082026185144_PressRelease11082026.pdf)
- 2026-08-11 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_11082026195203_AudioLink.pdf)
- 2026-08-11 — Management Change: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1852_WebXMLFile_20260811_203050566.xml)
- 2026-08-11 — Management Change: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_11082026195955_CombinedResults.pdf)
- 2026-08-11 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_11082026132215_OutcomeofBM.pdf)
- 2026-08-11 — Management Change: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_11082026200546_ChangeinDirectors.pdf)
- 2026-08-11 — Generic Announcement: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_11082026190609_SEIntimation11082026.pdf)
- 2026-08-11 — Press Release: Zydus Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Cadilahc_11082026132950_PressRelease.pdf)

## News and market events

- 2026-09-17 — BUSINESS: **Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak** — The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction. — [Source](https://www.business-standard.com/markets/capital-market-news/sensex-nifty-trade-in-positive-terrain-pharma-shares-snap-5-day-losing-streak-126091700646_1.html)
- 2026-09-15 — MONEYCONTROL: **Dr Reddy’s launches Opdivo biosimilar Nivorz in India, enters immuno-oncology segment** — Dr Reddy's, DRL, opdivo, nivorz biosimilar, oncology, cancers — [Source](https://www.moneycontrol.com/news/business/dr-reddy-s-launches-opdivo-biosimilar-nivorz-in-india-enters-immuno-oncology-segment-14030366.html)
- 2026-09-10 — Mint: **Govt plans central licensing for all sterile drugs after quality lapses | Today News** — The move is significant for India’s generic injectable industry, where manufacturing lapses can pose a more immediate risk to patients than defects in medicines taken orally. — [Source](https://www.livemint.com/news/govt-plans-central-licensing-for-all-sterile-drugs-after-240-injection-samples-fail-quality-tests-medicine-11789033517269.html)
- 2026-09-02 — BUSINESSTODAY: **SBI Funds, Zydus Life, CemIndia, GIC RE among stocks with fresh brokerage interest for upto 55% rise** — Top stocks to buy, Top stocks to watch, Top stocks in news, IC reports, Initiating coverage reports, fresh reports, Entero Healthcare Solutions, SBI Funds Management, CemIndia Projects, Seamec, General Insurance Corporation of India, Medi Assist Healthcare Services, Zydus Lifesciences, Entero Healthcare shares, SBI Funds shares, CemIndia shares, Seamec shares, GIC RE shares, Medi Assist shares, Zydus Life shares, Entero Healthcare target price, SBI Funds target price, CemIndia target price, Seamec target price, GIC RE target price, Medi Assist target price, Zydus Life target price — [Source](https://www.businesstoday.in/markets/stocks/story/sbi-funds-zydus-life-cemindia-gic-re-among-stocks-with-fresh-brokerage-interest-for-upto-55-rise-552804-2026-09-02)
- 2026-08-28 — Mint: **Raja Venkatraman recommends three stocks for 28 August** — Market expert Raja Venkatraman shares his top stock picks for 28 August. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-28-august-11787845434349.html)
- 2026-08-21 — The Hindu: **Zydus secures U.S. FDA nod for scurvy injection generic** — Zydus Lifesciences gains U.S. FDA approval for generic Ascorbic Acid Injection, used for treating scurvy, enhancing market competition. — [Source](https://www.thehindu.com/business/zydus-secures-us-fda-nod-for-scurvy-injection-generic/article71374689.ece)
- 2026-08-21 — Economic Times: **Zydus Lifesciences gets USFDA nod for generic ascorbic acid injection** — Zydus Lifesciences secured final USFDA approval for its generic ascorbic acid injection. This approval is for the treatment of scurvy in specific patient groups. The company's product is the generic equivalent of the Ascor injection. The USFDA designated this application as a Competitive Generic Therapy. Zydus will market the product in the United States market. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-lifesciences-gets-usfda-nod-for-generic-ascorbic-acid-injection/articleshow/133402397.cms)
- 2026-08-14 — BUSINESSTODAY: **PNB, Zydus Life, Oberoi Realty: Top stocks to trade — Key levels, target price & stop loss** — Stocks to buy, Stock picks, Stocks to trade, trading views, Zydus Lifesciences, Oberoi Realty, Punjab National Bank, Zydus Life shares, Oberoi Realty shares, Punjab National Bank shares, PNB shares, Zydus Life share price, Oberoi Realty share price, Punjab National Bank share price, PNB share price, Zydus Life stock price, Oberoi Realty stock price, Punjab National Bank stock price, PNB stock price, Zydus Life target price, Oberoi Realty target price, Punjab National Bank target price, PNB target price — [Source](https://www.businesstoday.in/markets/stocks/story/pnb-zydus-life-oberoi-realty-top-stocks-to-trade-key-levels-target-price-stop-loss-549108-2026-08-14)
- 2026-08-12 — Economic Times: **Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked target** — Shares of Zydus Lifesciences saw a decline of more than two percent following the announcement of a notable profit drop. The net profit plunged thirty-six percent year-on-year for the first quarter, despite a nearly twenty-two percent increase in operational revenue. Expenses surged by over forty-one percent. However, the managing director remains optimistic about future prospects. Analysts at Nuvama have upgraded the stock to 'Buy', setting a higher price target. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/zydus-lifesciences-shares-drop-3-after-q1-earnings-heres-why-nuvama-upgraded-rating-hiked-target/articleshow/133169721.cms)
- 2026-08-12 — MONEYCONTROL: **Price Action | Dr Agarwals Health Care, Tenneco Clean Air India slip on block deals; RHI Magnesita falls nearly 5%** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/price-action-dr-agarwals-health-care-tenneco-clean-air-india-slip-on-block-deals-rhi-magnesita-falls-nearly-5-14002428.html)
- 2026-08-12 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: GIFT Nifty indicates muted open; Godrej Consumer shares in focus** — Sensex Today | Stock Market LIVE Updates: The Nifty 50 index finds itself at a crucial juncture ahead of the mid-week trading session with 24,500 still being the decisive level to watch on either side. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-it-godrej-consumer-thyrocare-dr-agarwal-tenneco-blocks-hal-pi-ind-share-price-liveblog-19967084.htm)
- 2026-08-11 — Times of India: **Zydus Life Q1 PAT falls 36% to Rs 940 crore as revenue rises 22%** — Zydus Lifesciences Q1 FY27: PAT down 36% to Rs 940 cr as revenue rose 22% to Rs 8,017 cr; margins fell; US biosimilar launch and Assertio buy. — [Source](https://timesofindia.indiatimes.com/city/ahmedabad/zydus-life-q1-pat-falls-36-to-rs-940-crore-as-revenue-rises-22/articleshow/133155597.cms)
- 2026-08-11 — CNBC-TV18: **Stock market fall explained: Why Sensex dropped 388 points, Nifty slipped below 24,500** — The Sensex fell 388 points to 78,154, while the Nifty dropped 112 points to 24,472. The Nifty Bank slipped 241 points to 57,446, while the Midcap index declined 12 points to 63,843. — [Source](https://www.cnbctv18.com/market/stock-market-fall-explained-why-sensex-dropped-388-points-nifty-slipped-below-24500-19966639.htm)
- 2026-08-11 — CNBC-TV18: **Zydus Lifesciences Q1 Results: Stock jumps over 6%; India biz leads growth** — Zydus Life's North American formulations sales were down 2.6% from last year and up 4.9% sequentially at ₹3,098 crore. The company said the same was driven by sustained volume expansion and new launches. — [Source](https://www.cnbctv18.com/market/zydus-lifesciences-share-price-india-us-formulations-sales-outlook-profit-share-price-19966516.htm)
- 2026-08-11 — CNBC-TV18: **Q1 Results LIVE Updates: Zydus Life profit down 36%; Hind Rectifiers shares down 8%** — Q1 Results LIVE Updates: MRF, Ashoka Building, Zydus Life, Bata India, Gokaldas Exports, Balrampur Chini, DAM Capital, EPack Durable, Delta Corp, Finolex Cables, JSW Paints, KPI Green, Landmark Cars, Manappuram Finance, Laxmi Dental, NBCC, RVNL, Senco Gold, Siemens Ltd, TD Power Systems, Venky's, are among the companies reporting their results today. Earnings reactions will come from Vodafone Idea, Bosch, Zee Entertainment, Gland Pharma, among other companies. Watch this space for all the LIVE result updates for Q1. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-vodafone-idea-bosch-mrf-bata-manappuram-nbcc-rvnl-zydus-life-zee-gland-ideaforge-share-price-liveblog-19966154.htm)
- 2026-08-11 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty down 120 points; Max Health, Tata Consumer top losers** — Sensex Today | Stock Market LIVE Updates: We are in the second half of this expiry session, and the bears are relentless. The markets are still under pressure, with the Nifty falling close to a 130 points, falling below the 24,450 mark. The Nifty Bank is under pressure, falling over 400 points, falling to 57,300. IndiGo, Tata Consumer and Axis Bank are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-expiry-today-oil-adani-bse-wipro-vedanta-vodafone-idea-rvnl-share-price-liveblog-19966134.htm)
- 2026-08-11 — The Hindu: **Q1 Results Today Live: MRF, Zydus Lifesciences, KPI Green Q1 PAT decline, Siemens, RVNL, PI Industries, Manappuram Finance, NBCC, Kalpataru, Swan Defence, Bata, Gujarat Energy to announce Q1 results** — Q1 Results Today, 11th August 2026 Live Updates:  Follow Q1FY27 live updates from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-siemens-zydus-lifescience-mrf-rvnl-pi-industries-manappuram-finance-nbcc-kalpataru-swan-defence-bata-gujarat-energy-kpi-green-vi-bosch-zee-results-11-august-2026/article71327946.ece)

## Business profile

**Strategic vision:** Global healthcare provider developing and marketing pharmaceutical products.

### Business segments
- **Pharmaceuticals and Healthcare:** Engaged in research, development, manufacturing, and marketing of active pharmaceutical ingredients, formulations, vaccines, biosimilars, and complex products.
- **Animal Health:** Develops and markets products for the animal health sector.
- **Wellness Products:** Offers a range of wellness products aimed at improving overall health.

### Competitive strengths
- Fully integrated global healthcare provider
- Comprehensive capabilities across the pharmaceutical value chain
- Significant global manufacturing footprint

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/zyduslife
Markdown representation: https://faxioms.com/stocks/zyduslife?render=md